Mizuho Securities Reiterates Buy on Tiffany & Co. (TIF) Following 3Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Tiffany & Co. (TIF) PT Range Raised at Wells Fargo Following Solid Q3 But Remains 'Underperform'
November 29, 2016 11:27 AM ESTWells Fargo analyst Ike Boruchow raised his valuation range on Tiffany & Co. (NYSE: TIF) to $70-$72 (from $64-$66) following "solid" Q3 results but maintained an Underperform rating.
Boruchow commented, "TIFs Q3 print was solid. While expectations had been coming up over the past several months (on the view that global luxury was beginning to improve), TIF was able to match those expectations with better comps and EPS. The single biggest driver of upside (vs. our model) came out of Japan which... More
Pre-Open Stock Movers 11/29: (CYTR) (VBLT) (THO) Higher; (NVLS) (FOLD) (SCVL) Lower (more...)
November 29, 2016 9:18 AM ESTToday's Pre-Open Stock Movers
Nivalis Therapeutics (NASDAQ: NVLS) 53.6% LOWER; announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction... More
Health stocks boost Wall Street; energy a drag
November 29, 2016 7:33 AM ESTBy Caroline Valetkevitch
(Reuters) - U.S. stocks edged higher on Tuesday as an upbeat outlook from UnitedHealth lifted health insurers, though a sharp drop in oil prices weighed on energy shares and limited the advance.
The day's small gains followed a decline in the market on Monday. Analysts said the post-U.S. election rally may be losing momentum, wit the S&P 500 now up roughly 8 percent for the year to date.
Wall Street has risen sharply following Donald Trump's White House win, helped in part by investor expectations that his plans to increase infrastructure spending,... More
Jeweler Tiffany posts first sales rise in eight quarters
November 29, 2016 7:03 AM ESTBy Abhijith Ganapavaram
(Reuters) - Tiffany & Co (NYSE: TIF) reported its first rise in sales in two years as more people shopped in its stores in Japan and China, and the upscale jeweler said sales in the United States declined at their slowest quarterly pace this year.
The company's shares rose as much as 8 percent on Tuesday, their highest in 15 months.
However, the luxury retailer - whose flagship store is next to the Trump Tower in New York - said it could not guarantee that sales in the current quarter... More
Tiffany & Co. (TIF) Tops Q3 EPS by 8c; Comps Outpaced
November 29, 2016 6:41 AM ESTTiffany & Co. (NYSE: TIF) reported Q3 EPS of $0.76, $0.08 better than the analyst estimate of $0.68. Revenue for the quarter came in at $949.3 million versus the consensus estimate of $922.6 million.
Constant currency comps fell 3 percent, versus a drop of 4.1 percent expected by analysts.
Sales Summary:
In the Americas, total sales of $417 million in the third quarter were 2% below the prior year, and sales of $1.25 billion in the year-to-date were 7% below the... MoreOptions expected to have Increasing volume: TIF USO UCO XOP XLE BP XOM ADSK KR
November 29, 2016 6:17 AM ESTOptions expected to have Increasing volume: TIF USO UCO XOP XLE BP XOM ADSK KR
... MoreOptions with increasing put volume on November 28; HUN WBMC UNT IM PWR SES TIF TSL
November 29, 2016 6:14 AM ESTOptions with increasing put volume on November 28; HUN WBMC UNT IM PWR SES TIF TSL
... MoreTiffany & Co (TIF) December 78.50 straddle priced for movement of 6.1% into Q3
November 28, 2016 3:14 PM ESTTiffany & Co (TIF) December 78.50 straddle priced for movement of 6.1% into Q3
... MoreTrading Radar for 11/29: BNS (BNS), Tiffany (TIF), Autodesk (ADSK), Splunk (SPLK) Report
November 28, 2016 1:30 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
9:00am EST
Case-Shiller 20-City Index - Street sees... MoreTiffany & Co (TIF) volatility increases to into Q3
November 28, 2016 11:14 AM ESTTiffany & Co. (NYSE: TIF) December weekly call option implied volatility is at 77, December is at 41; compared to its 52-week range of 21 to 44 into the expected release of Q3 results on November 29
... More